Evidence map›Paper›PMID 19372484›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2009

Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor.

Mai Johnson, Breanne D W Karanikolas, Saul J Priceman, Russell Powell, Margaret E Black, Hsiao-Ming Wu, Johannes Czernin, Sung-Cheng Huang, Lily Wu

Open access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular imaging of prostate cancer: PET radiotracers.AJR. American journal of roentgenology · 2012
    Review
  4. In vivo imaging of intraprostatic-specific gene transcription by PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2011
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mai JohnsonDepartment of Molecular, Cellular and Integrative Physiology, UCLA, Los Angeles, CA, USA.
Breanne D W Karanikolas
Saul J Priceman
Russell Powell
Margaret E Black
Hsiao-Ming Wu
Johannes Czernin
Sung-Cheng Huang
Lily Wu
University of California, Los Angeles · USWashington State University · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
Gene-Based Imaging and Therapy To Target Prostate CancerR01CA101904 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, LILY · 2003 to 2012
$2.9M
PET-guided Intervention in Lymphatic Metastasis of Prostate CancerR21CA122693 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, LILY · 2007 to 2008
$340k
NCI NIH HHS CA-16042NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA101904NCI NIH HHS R21 CA122693NCI NIH HHS T32 CA009056NIAID NIH HHS AI-28697NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

unlabelledBecause of its high selectivity and specificity for the imaging reporter probe 9-(4-(18)F-fluoro-3-[hydroxymethyl]butyl)guanine ((18)F-FHBG), the herpes simplex virus type 1 thymidine kinase (HSV1-tk) variant sr39tk is actively being studied as a PET reporter gene. We recently demonstrated the capability of using a prostate-specific transcriptional amplification PET reporter vector, AdTSTA-sr39tk, to target prostate cancer lymph node metastasis. However, one area that warrants further study is the examination of the sensitivity of PET by determining the minimum percentage of cells expressing the sr39tk transgene needed for detection. Addressing this question could determine the sensitivity of vector-mediated sr39tk PET in cancer-targeting strategies.

methodsDU-145, PC-3, and CWR22Rv.1 prostate cancer cell lines (a total of 1 x 10(6) cells) were studied, of which 7%, 10%, 25%, 50%, or 70% were transduced with the lentiviral vector constitutively expressing HSV1-sr39tk-IRES-enhanced green fluorescent protein (EGFP). Cells were subcutaneously implanted into the left shoulder of severe combined immunodeficient mice and evaluated. Tumor cells comparably transduced with an EGFP control vector were implanted on the right shoulder. Mice were imaged using PET with (18)F-FHBG at 8, 15, and 22 d after tumor implant. On day 23, tumors were isolated and analyzed for sr39tk transgene expression by quantitative reverse-transcriptase polymerase chain reaction (RT-PCR), Western blotting, immunohistochemistry, and flow cytometry for EGFP expression.

resultsResults showed a linear relationship between the level of sr39tk expression and the quantity of tracer accrual in DU-145, with the minimal value for PET detection at 10%. The magnitude of tracer retention in sr39tk-expressing cells was amplified over time as the tumor grew. Protein levels in the stepwise titration increased with the percentage of sr39tk-transduced cells.

conclusionThe stepwise titration of prostate cancer cells transduced with the lenti-CMV-sr39tk-IRES-EGFP determined the minimum number of sr39tk-expressing tumor cells necessary to be detected by PET using the (18)F-FHBG reporter probe. Furthermore, PET signal correlated well with traditional methods of protein evaluation such as flow cytometry, quantitative RT-PCR, Western blotting, and immunohistochemistry. Unlike the traditional methods, however, the use of PET is noninvasive and will be more advantageous in clinical situations.

Indexed as

AnimalsCell Line, TumorDrug Delivery SystemsGene ExpressionGuanineHerpesvirus 1, HumanLentivirusMaleMiceMolecular Probe TechniquesPositron-Emission TomographyProstatic NeoplasmsRadiopharmaceuticalsThymidine KinaseTransduction, Genetic9-(4-fluoro-3-hydroxymethylbutyl)guanineGuanineRadiopharmaceuticalsThymidine Kinase

Identifiers

PMID19372484
PMCPMC2805178
OpenAlexW2152806025

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.